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Running title: Standardized methods for TBM research 
 
40 word summary 
This viewpoint defines a tuberculous meningitis core dataset, including demographic and clinical 
information, key patient management and monitoring data, and standardized reporting of patient 
outcomes. Wide adoption of standardized methods will provide a robust evidence base to improve 
patient outcomes.   
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Abstract 
Tuberculous meningitis remains a major cause of death and disability in tuberculosis endemic areas, 
especially in young children and immunocompromised adults. Research aimed at improving 
outcomes is hampered by poor standardization, which limits study comparison and the generalizability 
of results. We propose standardized methods for the conduct of tuberculous meningitis clinical 
research that were drafted at an international tuberculous meningitis research meeting organized by 
the Oxford University Clinical Research Unit in Vietnam. We propose a core dataset including 
demographic and clinical information to be collected at study enrolment, important aspects related to 
patient management and monitoring, and standardized reporting of patient outcomes. The criteria 
proposed for the conduct of observational and intervention tuberculous meningitis studies should 
improve the quality of future research outputs, facilitate multi-centre studies and meta-analyses of 
pooled data, and could provide the foundation for a global tuberculous meningitis data repository. 
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INTRODUCTION 
Tuberculous meningitis (TBM) was almost universally fatal until the first antibiotic treatment with 
streptomycin and isoniazid became available [1]. TBM remains a major cause of disease, disability 
and death in tuberculosis endemic areas, but research aimed at improving outcomes is hampered by 
difficulties in patient recruitment and heterogeneous research methodology. The development of a 
consensus TBM case definition for use in TBM research has assisted new diagnostic studies by 
providing a uniform reference standard [2]. However, variable data collection methods, different 
disease classification systems and the absence of standardized outcome assessment continue to limit 
study comparison and complicate efforts to perform systematic reviews and meta-analyses.  
The need to standardize clinical trial endpoints is well-recognized for pulmonary and drug-resistant 
tuberculosis research and is the focus of several international consortia (for example, PreDICT-TB 
(www.predict-tb.eu), RESIST-TB (www.resisttb.org), and TREAT-TB (www.treattb.org)). Core 
research methods have been proposed for adults and children with multi-drug resistant tuberculosis 
[3, 4]. In this context, the Oxford University Clinical Research Unit in Vietnam (OUCRU), together with 
the University of Cape Town’s Clinical Infectious Diseases Research Initiative (CIDRI), organized a 
meeting of international TBM researchers in Dalat, Vietnam (20-22 May 2015) to assess recent 
progress and address key challenges in TBM research (see acknowledgements for list of 
participants).  Researchers actively engaged in TBM research worldwide, were invited with the aim of 
creating an international consortium that could make recommendations concerning the objectives and 
methodology of future TBM clinical research.  
A TBM research methodological framework was discussed and agreed during the meeting by all 
delegates, broadly defining the key baseline, treatment, and outcome data required in the conduct of 
TBM research. Thereafter, proposed essential and desirable data were circulated by the lead authors 
(BM, DH and GT) and agreed or adapted by the writing committee (all listed authors) until consensus 
was found. A statement thereby arose from the meeting, proposing standardized criteria for the 
conduct and reporting of TBM research and shared data collection templates. We provide an 
overview of the consensus reached by the consortium, identifying demographic and clinical 
information to be collected at study enrolment, important aspects related to patient management and 
monitoring, and standardized reporting of patient outcomes.  Specific data points were categorized as 
either essential or desirable. The essential data points are intended to define minimum criteria for the 
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conduct of both observational and intervention studies, and to identify a core dataset for universal use 
in future clinical research. Better harmonized research methods would improve the quality of research 
outputs, facilitate study comparison and may in future provide the foundation for a global TBM data 
repository.  
 
COHORT DESCRIPTION AND METHODS 
Adequate cohort description with clarification of the clinical “point of entry” is essential to ensure study 
reproducibility and to interrogate differences in study outcomes that may be unrelated to the 
intervention studied. Since treatment outcomes and diagnostic test performance may vary according 
to the severity of disease, age, immune status and patient management, the study population must be 
well characterized in terms of setting, inclusion criteria, demographics, human immunodeficiency virus 
(HIV) infection and immune status, disease classification and treatment received.  
 
INFORMATION TO COLLECT AT ENROLMENT  
Table 1 provides a summary of essential and desirable baseline information to be collected at study 
enrolment. Essential data points include information required by the previously published uniform 
TBM research case definition (Table 2) [2], which should be applied to ensure adequate diagnostic 
workup and to characterize the study cohort in a standardized fashion.  For diagnostic studies it is 
important to ensure that control subjects represent a credible clinical entry point for TBM diagnostic 
evaluation, in order to assess “real-life” diagnostic accuracy. 
Disease severity and phenotype  
Given the diversity of clinical presentation and disease severity it is important to grade TBM severity 
in a pragmatic and standardized fashion. As a minimum, HIV status (preferably with CD4 count and 
WHO clinical disease staging) must be recorded and the modified British Medical Research Council 
(BMRC) TBM grade (Textbox 1) should be ascertained in all studied patients before the start of 
treatment. BMRC investigators[1] first graded TBM patients as ‘early’ (no clinical signs of meningitis or 
focal neurology and fully conscious) ‘medium’ (patient’s condition falling between early and advanced) 
and ‘advanced’ (extremely ill, in deep coma).  With the introduction of the Glasgow coma score (GCS) 
in 1974 [5] this was modified as Grade I (GCS 15; no focal neurological signs), Grade II (GCS 11-14, 
or 15 with focal neurological signs) and Grade III (GCS≤10) disease [6]. Numerous studies across all 
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age groups have shown that the modified BMRC grade is a strong independent predictor of outcome 
[6-10]. TBM patients with grade I disease are often under-represented in studies, since their 
nonspecific symptoms may not trigger a lumbar puncture, which usually provides the entry point for 
TBM studies.  Sub-division of grade II disease has been proposed [11],as has other prognostic 
systems based on weighted scoring of mental status, seizures, cranial nerve palsies, motor deficit and 
tone [12], but these have not been validated. Because level of consciousness is influenced by rapidly 
reversible raised intracranial pressure and electrolyte disturbances, it is important to repeat the BMRC 
disease severity grading 7 days after TBM treatment initiation. This provides a useful reassessment of 
disease severity that may be better associated with long-term outcome than a single baseline 
assessment.  
Baseline investigations 
Essential and desired study investigations, to be performed at enrolment, are summarized in table 1. 
CSF sampling and analysis is essential to assist diagnostic workup, cohort description, and to define 
prognosis.  Low CSF white cell count, low glucose and high lactate have been associated with death 
in studies from Vietnam [13]. In HIV co-infected patients baseline CSF neutrophil count and culture 
positivity for Mycobacterium tuberculosis are predictive of TBM immune reconstitution inflammatory 
syndrome (IRIS) [14]. Cryptococcal meningitis and TBM have similar presenting features and CSF 
cryptococcal antigen tests should be performed, especially in those with advanced HIV (peripheral 
CD4+ T cells <100/µL) in whom both diseases are common. Peripheral blood findings have limited 
diagnostic or prognostic value, but it is important to document anaemia, determine baseline renal and 
liver function tests for drug toxicity monitoring and assess HIV and immune status. Hyponatraemia 
has been linked to a worse outcome [15], while in HIV-1 co-infected patients lower blood haematocrit 
[13] and low CD4+ T cell count [16] [17] have been associated with death.  
Brain computed tomography (CT) with/without contrast and magnetic resonance imaging (MRI) 
characterize the pathological processes underlying the clinical presentation, disease course and long-
term consequences of TBM. Baseline brain imaging is recommended for all patients, although may 
not be available in all settings [18]. Classic imaging findings include basal meningeal enhancement, 
hydrocephalus, tuberculomas and cerebral infarction [19]. MRI is more sensitive in detecting early 
ischemia and brainstem lesions [20]. TBM-related infarcts are most commonly located in the 
territories of the proximal middle cerebral artery and the medial lenticulostriate and thalamoperforating 
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vessels [21, 22]. Brain imaging provides a window on the pathophysiology of TBM and standardized 
documentation of these complications and their response to treatment could improve management 
and may suggest new therapeutic approaches. 
Sample collection and laboratory methods 
Diagnostic yield is influenced by both the type and quality of specimens collected, therefore careful 
description of specimen collection methods and test procedures are important. Microbiological yield is 
affected by cerebrospinal fluid (CSF) volume, sample transport delays and processing techniques 
[23]. The CSF sample volume used for each mycobacterial diagnostic test should be reported. In 
addition, adequate quality assurance of all research laboratories is essential to ensure test reliability.   
 
MANAGEMENT AND MONITORING 
Ensuring minimal standards of ancillary care and patient monitoring is essential for ethical reasons 
and for reporting purposes, since differences in local management practices are important 
confounders when assessing outcomes. Management and monitoring protocols should be adequately 
described including: 1) anti-tuberculosis drug treatment, 2) adjunctive anti-inflammatory therapy, 3) 
management of hydrocephalus and 4) other supportive care (table 3).  
 
Anti-tuberculosis drug treatment 
As summarised in table 3, it is essential to document the dose, route of administration, and duration 
of all anti-tuberculosis drugs used in TBM treatment. Anti-tuberculosis drug-related adverse events 
are more important in the treatment of TBM than other forms of tuberculosis because treatment 
interruptions have been independently associated with death [24]. Drug-induced liver injury (DILI) is 
the commonest adverse event and should be documented, alongside changes in anti-tuberculosis 
drug regimen. Outstanding questions remain concerning optimal management when DILI occurs and 
harmonised data collection would allow analyses to address these.  
If performing anti-tuberculosis drug treatment trials it is important to document drug quality, since this 
can be highly variable. WHO pre-qualified drugs have been rigorously evaluated and meet strict 
quality criteria (a list of pre-qualified drugs is available at 
http://apps.who.int/prequal/query/ProductRegistry.aspx). For other drugs, pharmaceutical companies 
should provide ‘certificates of analysis’ and data on bio-equivalence.  
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Pharmacokinetic/dynamic sub-studies 
Pharmacokinetic/dynamic sub-studies can help to explain trial findings and provide important dosing 
information for future studies. Evaluation of individual exposures achieved provides insight into 
predictors of drug exposure and enables concentration-response relationships (PK-PD analysis) to be 
established [25-27]; the latter may reveal exposure thresholds predictive of good treatment outcome 
or drug toxicity [26, 28, 29].   Pharmacokinetic analysis should ideally include both plasma and CSF 
measurements, although CSF concentrations may not reflect the brain tissue concentration of highly 
lipophilic drugs [30, 31]. Pharmacokinetic studies often take place at ‘steady state’, when the 
processes of accumulation or induction are complete (in rifampicin this can take up to 10 days), but in 
TBM we suggest measuring exposures during the critical first days of treatment when mortality is 
highest [27]. CSF sampling after weeks of treatment may yield different results, as CSF drug 
penetration may reduce as meningeal inflammation lessens.  
The standard method to assess CSF penetration is the CSF:plasma ratio for total drug exposure 
(area under the concentration versus time curve, AUC) during the dosing interval, which requires 
multiple plasma and CSF samples [25]. Alternatively a CSF:plasma concentration ratio can be 
established by a single point measurement, but this is time dependent since the ratio is often variable 
over the dosing interval [31]. Although single time point CSF:plasma ratios should be interpreted with 
caution, pharmacokinetic modeling may approximate the CSF:plasma AUC ratio despite limited 
sampling, if such sampling takes place at multiple time points. It is important that CSF:plasma 
concentration ratios should be based upon estimated protein-unbound (‘free’) exposure measures. In 
plasma, only the protein-unbound fraction is active and able to penetrate into the CSF. If a drug with 
high protein binding in plasma has excellent CSF penetration, a CSF:plasma ratio  based on protein-
unbound concentrations would be close to unity. In contrast, a ratio based on total (bound + unbound) 
concentrations would incorrectly suggest poor penetration [31]; as is the case with rifampicin. 
Therefore a correction for protein binding of plasma concentrations should always be made [26] [25].  
Pharmacokinetic sampling can be ‘intensive’ or ‘sparse’, or ideally a mixture of both to assist accurate 
modelling. Analytical methods used to determine drug concentrations should have appropriate 
intralaboratory (internal) assessment of accuracy, precision and other validation measures. 
Participation in an interlaboratory (external) proficiency testing program is recommended [32]. Of 
note, CSF drug concentrations cannot be measured using plasma assays without careful validation.   
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Adjunctive anti-inflammatory therapy 
TBM studies should describe the type, dose, route of administration, and duration of anti-inflammatory 
therapy used (table 3). Adjunctive corticosteroids are currently recommended for all HIV-uninfected 
TBM patients during the first 6-8 weeks of treatment [9]; they are also used in HIV-infected patients, 
although the evidence of benefit is much less clear. Corticosteroids are also often used for the 
management of tuberculomas and IRIS in HIV-infected patients, although the evidence base is weak. 
Some patients who do not respond to corticosteroids may benefit from other agents, such as 
thalidomide or anti-TNF-α biologic agents [33-36]. Two small studies also suggest that aspirin may 
reduce cerebral infarcts [37, 38], but this has not been confirmed in larger scale studies.  
Management of hydrocephalus  
As a minimum, the presence of hydrocephalus assessed by brain CT or MRI should be documented 
at the start of treatment. An assessment of whether the hydrocephalus is communicating or non-
communicating is desirable, and the management (medical or surgical) documented (table 3). Raised 
intracranial pressure, largely due to hydrocephalus, is a common problem in patients with TBM [10, 
39]. If untreated, hydrocephalus can exacerbate the cerebral ischaemia caused by perfusion-limiting 
vasculitis, which is a key feature of TBM. Untreated hydrocephalus is independently associated with 
death [40, 41]. Whether the hydrocephalus is communicating or non-communicating [10, 42] has 
important management implications. At present, the only way to reliably differentiate communicating 
from non-communicating hydrocephalus is with an air encephalogram or using contrast 
ventriculography [43, 44]. Performing an air encephalogram does not require any special resources 
and can be performed when collecting a CSF sample. Ventricular shunting is usually indicated for 
non-communicating hydrocephalus, while a combination of diuretics (acetazolamide and furosemide) 
may treat communicating hydrocephalus [45]; the value of this approach requires further confirmation 
in adults.  
General supportive care 
The provision of optimal supportive care in TBM patients is rarely reported and often neglected and 
therefore highlighted here. Hyponatraemia occurs in a high percentage of TBM patients, is associated 
with poorer outcome [10], and should be documented (table 3). Hyponatremia may result from 
inappropriate antidiuretic hormone (ADH) secretion, cerebral salt wasting or represent an appropriate 
compensatory response to maintain cerebral perfusion. Plasma sodium concentrations should be 
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recorded at baseline and through the early phase of hospital treatment. In critically ill patients 
changes in cerebral perfusion and oxygenation are highly dynamic, but can be captured through 
continuous intracranial monitoring. This is invasive and only possible during intensive care admission 
in settings where the facilities exist. Transcranial Doppler [46] and near-infrared spectroscopy provide 
less invasive alternatives, but these methods require more rigorous validation and have not yet 
demonstrated clinical utility. Simple measures to reduce cerebral ischaemia and brain cell metabolic 
stress include maintaining adequate blood pressure and glucose levels, providing supplemental 
oxygen and controlling fever [47].  These parameters should be recorded in all critically ill patients 
(table 3). 
 
OUTCOME MEASURES 
The inconsistent reporting of outcome measures limits critical study evaluation and comparison. TBM 
is associated with high mortality; therefore death is an essential outcome measure. The time of death 
in relation to the start of anti-tuberculosis treatment should also be documented and we recommend 
reporting to at least 12 months from anti-tuberculosis treatment initiation. Cause of death is 
notoriously difficult to determine without formal post-mortem examination, but deaths directly 
attributable to TBM are more likely to occur in the first 3-months of treatment; later deaths may be 
caused by secondary infections, for example, especially in those left with severe neurological 
disability. An assessment by the attending physician as to the likely cause of death (TBM-
attributable/not-attributable) is desirable, but not essential given the inherent limitations of this 
approach.  
The reporting of functional outcomes are also essential, but different measures are used [9], and 
detailed neurocognitive outcomes are rarely assessed [48]. Given the importance of neuro-disability 
and comparable outcome measurement, we recommend that the Modified Rankin Score should be 
recorded 12 months from anti-tuberculosis treatment initiation in all adults and in children. The score 
(detailed in the supplementary appendix) assesses whether or not the subject can live independently 
of others. We also recommend recording the Pediatric Version of the Glasgow Outcome Scale–
Extended (GOS-E peds) in children (table 4); although this scale, created for children following 
neurotrauma, needs further validation in childhood TBM.   
TBM causes significant long-term neurocognitive impairment in children [10], [49] and adults[7] and 
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detailed neurocognitive and psychiatric outcomes should be reported where possible. The Griffiths 
Mental Developmental Scales or the Paediatric Cerebral Performance Category Scale provides 
assessment on age-appropriate neurocognitive and developmental outcomes. It is important that 
children are compared to age-matched controls from the same socio-economic background, given 
major environmental influences on early cognitive development.   
 
Paradoxical reactions 
Clinical deterioration after the start of anti-tuberculosis treatment - commonly called paradoxical 
reactions and associated with increased intracerebral inflammation - occurs in around 30% of HIV-
uninfected individuals with TBM [50] and around 50% of those HIV-infected [14]. Paradoxical 
reactions are associated with new or worsening intra-cerebral tuberculomas, hydrocephalus, infarcts, 
and/or spinal radiculomyelitis. In HIV-infected subjects recently started on anti-retroviral therapy these 
events may be defined as TBM- IRIS following the International Network for the Study of HIV-
associated IRIS (INSHI) criteria [51], modified for TBM. 
All suspected paradoxical reactions and their timing with respect to anti-tuberculosis drug initiation 
should be recorded (table 4). When possible investigate all suspected paradoxical reactions with 
brain imaging and document the findings, management given, and outcomes. Alternative causes that 
should be excluded as far as possible include drug resistance, poor adherence to treatment, drug-
related adverse events, and other opportunistic infections. We also recommend that all WHO HIV 
Stage 4 illnesses should be recorded throughout the course of TBM treatment (table 4). 
 
PROPOSED CORE DATASET 
Participants at the workshop reinforced calls for standardized approaches, including laboratory and 
clinical assessment procedures and data reporting.  All laboratory tests should be guided by detailed 
standard operating procedures (SOPs), including sample collection, processing, transport, storage 
and laboratory procedures for specific diagnostic tests, including quality assurance measures; 
relevant SOPs are included in the on-line supplementary information. Demographic and clinical 
data should also be collected in a standardized fashion.  The essential elements listed in the tables 
provide the basis for a core dataset that represents the minimum data to be captured in future TBM 
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studies.  A proposed data capture form that includes all the proposed ‘essential’ and ‘desirable’ 
variables (tables 1, 3, 4) is included (on-line supplement).    
 
CONCLUSION  
Developing standardized approaches represents a critical first step to establish the evidence base 
required to improve TBM detection and outcome. Poor study comparability due to variable methods, 
case definitions, data collection and reporting, highlight the inadequacy of current approaches. Wide 
adoption of the standard methods proposed here should help to move the field forward and ensure 
that the benefits of technological advances are fully realized. This document should be viewed as a 
living tool that will be refined as the evidence base and field experience with conducting multicenter 
TBM studies grow and are critically evaluated at future meetings. 
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Figures 
Figure 1.  
 
Proposed minimum schedule of investigations and outcome measurements in TBM studies. 
TBM – tuberculous meningitis; LFTs – liver function tests; HIV – human immunodeficiency virus; ART 
– antiretroviral therapy; IRIS – immune reconstitution inflammatory syndrome; DST – drug 
susceptibility testing 
 
 
 
 
Textbox 1.  
 
Modified British Medical Research Council TBM staging 
 
 
 
 
 
 
GCS – Glasgow coma score 
 
 
 
 
 
 
 
  
Grade l  GCS 15 with no focal neurological signs 
Grade ll  GCS 11-14; or 15 with focal neurological signs 
Grade lll GCS ≤10 
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Table 1. Baseline information to be collected at enrolment in TBM studies 
 
Information Essential Desirable  
Demographics Age (date of birth) 
Gender 
- Nationality, ethnicity 
- Medical facility 
Presenting 
symptoms 
 
Neurological symptoms (headache, vomiting, 
convulsions) - duration* 
Systemic symptoms (weight loss, night sweats, 
cough, fever) - duration* 
 
 
 
Medical history 
 
Previous and/or current TB 
Previous TB preventive therapy 
HIV infection / ART 
Diabetes (use of insulin) 
In children  
BCG vaccination/scar 
Recent TB contact*
1
 
- Number of previous TB episodes; date 
most recent treatment/preventive therapy; 
regimen used; adherence 
- History of IV drug use 
- BCG vaccination/scar (adults) 
Clinical findings 
 
 
Weight (true or estimate) 
Glasgow coma score* 
Cranial nerve palsy or other focal neurological 
deficit (specify)* 
In children 
Modified Glasgow Coma Scale for infants 
Head circumference (<5yrs) 
Weight and failure to thrive  
- Height 
- Neck stiffness 
- Convulsions (focal or generalised) 
- Papilledema or other signs of raised 
intracranial pressure 
Laboratory 
investigations  
 
CSF  
Appearance* 
Total & differential white cell count* 
Protein & glucose* 
India ink stain (and/or cryptococcal antigen)* 
Mycobacterial culture (and/or NAAT) and drug 
susceptibility testing *
3
 
Extraneural samples   
ZN stain*; Mycobacterial culture (and/or NAAT)*
3
 
Peripheral blood 
FBC with differential white cell count 
Plasma glucose (paired with CSF), sodium, 
potassium, urea and creatinine 
Liver transaminases (AST, ALT baseline) 
HIV test (if not known to be positive) 
In children 
TST and/or IGRA* 
CSF  
- Collection site (lumbar, ventricular) 
- Volume (for TB investigations)  
- Ziehl-Neelsen (ZN) stain
2
 
- Lactate 
- Opening pressure  
- Additional tests to exclude alternative 
diagnoses e.g. bacterial and fungal culture, 
enterovirus PCR 
 
- IGRA or TST (adults) 
- Hepatitis B or C co-infection 
- Syphilis serology 
Imaging 
 
Chest radiograph  
Signs of active TB*; miliary appearance  
 
Brain CT or MRI* 
Hydrocephalus; basal meningeal enhancement, 
infarct, tuberculoma 
 
- Imaging (MRI/CT/ultrasound) of extra-
neural sites suspected of TB disease* 
- Air encephalogram to differentiate  
communicating and non-communicating 
hydrocephalus 
- Hydrocephalus description; presence of 
periventricular oedema; herniation  
- Infarct; type; single/multiple; anatomical 
location 
Diagnostic 
certainty  & 
disease severity  
Definite, Probable, Possible or Not TBM* 
BMRC TBM severity grade
4
 (1,2 or 3) 
 
If HIV infected WHO clinical disease staging  
CD4 count  
ART 
CD4 count (most recent and nadir) 
HIV viral load (most recent and highest)  
Detail of ART regimen 
 at Im
perial College London on D
ecem
ber 23, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
20 
 
 
*Data required for uniform TBM research case definition criteria (Table 2)  
TB – tuberculosis; TBM - tuberculous meningitis; NAAT - nucleic acid amplification test, including 
GeneXpert MTB/RIF®; TST - tuberculin skin test, IGRA - interferon gamma-release assay, CSF - 
cerebrospinal fluid; CT - computed tomography; MRI - magnetic resonance imaging; BMRC - British 
Medical Research Council; HIV – human immunodeficiency virus; ART – antiretroviral therapy; WHO 
– World Health Organization 
1
Close/household contact with an infectious (pulmonary) TB case during the past year; 
2
The yield of 
CSF ZN microscopy is so low that many laboratories don’t offer this as a routine test; 
3
Genotypic (at 
least GeneXpert MTB/RIF®) or phenotypic drug susceptibility testing must be performed if M. 
Tuberculosis detected; 
4
According to modified British Medical Research Council criteria (Textbox 1)  
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Table 2. Uniform TBM research case definition criteria 
3 
 
Clinical criteria (Maximum category score=6) 
Symptom duration of more than 5 days 4 
Systemic symptoms suggestive of TB (1 or more of ): weight loss/(poor weight 
gain in children), night sweats or persistent cough > 2 weeks 
2 
History of recent close contact with an individual with pulmonary TB or a positive 
TST/IGRA in a child <10 years 
2 
Focal neurological deficit (excluding cranial nerve palsies) 1 
Cranial nerve palsy 1 
Altered consciousness 1 
CSF criteria (Maximum category score=4) 
Clear appearance 1 
Cells: 10–500 per μl 1 
Lymphocytic predominance (>50%) 1 
Protein concentration greater than 1 g/L 1 
CSF to plasma glucose ratio of less than 50% or an absolute CSF glucose 
concentration less than 2.2mmol/L 
1 
Cerebral imaging criteria (Maximum category score=6) 
Hydrocephalus (CT and/or MRI) 1 
Basal meningeal enhancement (CT and/or MRI) 2 
Tuberculoma (CT and/or MRI) 2 
Infarct (CT and/or MRI) 1 
Pre-contrast basal hyperdensity (CT) 2 
Evidence of tuberculosis elsewhere (Maximum category score=4) 
Chest radiograph suggestive of active TB (excludes miliary TB) 2 
Chest radiograph suggestive of miliary TB 4 
CT/ MRI/ US evidence for TB outside the CNS 2 
AFB identified or M. tuberculosis cultured from another source i.e., sputum, lymph 
node, gastric washing, urine, blood culture 
4 
Positive commercial M tuberculosis NAAT from extra-neural specimen                             4 
Exclusion of alternative diagnoses- An alternative diagnosis must be confirmed 
microbiologically, serologically or histopathologically 
Definite TBM =AFB seen on CSF microscopy, positive CSF M. tuberculosis culture, or 
positive CSF M. tuberculosis commercial NAAT in the setting of symptoms/signs 
suggestive of meningitis; or AFB seen in the context of histological changes consistent 
with TB brain or spinal cord together with suggestive symptoms/signs and CSF changes, 
or visible meningitis (on autopsy). 
Probable TBM = total score of ≥12 when neuroimaging available 
                         = total score of ≥10 when neuroimaging unavailable 
At least 2 points should either come from CSF or cerebral imaging criteria 
Possible TBM = total score of 6-11 when neuroimaging available 
                         = total score of 6-9 when neuroimaging unavailable 
 
TBM - tuberculous meningitis, TB - tuberculosis, TST - tuberculin skin test, IGRA - interferon gamma-
release assay, CSF - cerebrospinal fluid, CT - computed tomography, MRI - magnetic resonance 
imaging, US - ultrasound, AFB - acid-fast bacilli, NAAT - nucleic acid amplification test 
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Table 3. Data collection requirements for patient management and monitoring in TBM studies 
 
Requirements Essential  Desirable 
Management 
 
TB treatment 
Initiation date 
Drug doses & route of administration 
Treatment duration & adherence  
Anti-inflammatory treatment 
Corticosteroids and/or other anti-
inflammatory agents (type, dose, duration) 
Hydrocephalus management  
Medical (drugs, dose, duration) 
Surgical (shunt type) 
ART 
Initiation date (if new) 
Regimen used   
Treatment adherence 
Time from TBM treatment to ART initiation  
TB treatment related adverse events 
(especially drug-induced liver injury) 
 
Surgery related adverse events 
Description of adverse events 
Time to shunt  
 
ART related adverse effects 
Treatment interruptions (number, total 
duration)  
 
Monitoring 
 
 
 
 
 
 
 
Observations
1
 
Level of consciousness 
Change in TBM severity grade (day 7) 
 
Blood tests
3
 
Full blood count  
Serum sodium, potassium, urea and 
creatinine  
Liver transaminases (ALT, AST) 
CSF 
2
 
Opening pressure; cell count and 
differential; protein, glucose; Ziehl-
Neelsen stain and mycobacterial 
culture and DST 
 
During acute illness record
1
 lowest 
blood pressure; pulse oximetry; blood 
sugar 
 
If admitted to ICU 
Blood gas; continuous intracranial 
pressure and cerebral 
oxygenation/perfusion monitoring
 
If HIV-infected 
CD4 T-cell count 3, 6 & 12 months  
HIV viral load 6 & 12 months 
 TBM – tuberculous meningitis; TB – tuberculosis; HIV – human immunodeficiency virus; ART – 
antiretroviral therapy; ICU – intensive care unit; DST – drug susceptibility testing 
 1
As a minimum clinical observations should be performed daily during the first 7 days, weekly during the 
first month and monthly during the first 6 months; 
2
 If the diagnosis of TBM is uncertain repeat CSF 
analysis 3-7 days after the start of treatment is recommended. Otherwise, CSF after 30 and 60 days of 
treatment can help assess treatment response and likelihood of drug-resistance; 
3
As a minimum blood 
tests should be performed at diagnosis, weekly during the first month and monthly during the first 6 
months  
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Table 4. Primary and secondary outcome measures to be reported in TBM studies  
 
ALL PATIENTS Essential  Desirable 
Primary outcomes 
(assessed 12 months from 
start of anti-TB treatment) 
Death; time-to-death  
Neurological disability
1
 
Cause of death
2 
Detailed neurocognitive 
and behavioural outcomes 
Secondary outcomes Coma clearance
3
; time-to-
event
 
New neurological event 
4
; 
time-to-event 
Change in TBM severity 
grade by day 7 of anti-TB 
treatment 
Coma management 
Radiological findings 
(brain imaging) 
investigating new 
neurological event 
 All serious adverse events 
5 
and their relationship to the 
disease or drugs given 
 
Anti-TB drug treatment 
interruptions (number, 
total duration)  
Time-to-event; likely 
causative agent; 
management  
Complications related to 
corticosteroid therapy 
 Time to hospital discharge
 
Admission to an intensive 
care-unit; duration of 
admission 
Requires mechanical 
ventilation; duration of 
ventilation 
HIV-INFECTED PATIENTS 
New stage 4 illnesses  Nature of condition; time-to-
event  
Management of condition 
Neurological TB-IRIS Nature of condition; time-to-
event  
Report TB-IRIS criteria used 
Management of condition 
 
TBM – tuberculous meningitis; IRIS – immune reconstitution inflammatory syndrome  
1
 Use modified Rankin score in adults and children, and the GOS-E (pediatric version of the Glasgow 
Outcome Scale–Extended) score in children - see online supplement for scoring criteria; 
2
 Cause of death 
should be reported as TBM-attributable or not attributable (determined by post mortem and/or clinical 
records); 
3
 from TBM treatment initiation until Glasgow coma score of 15 for two consecutive days; 
4
 
Defined as a fall in GCS of ≥2 points for ≥48 hours, new focal neurological sign, or new onset of seizures; 
5
 any adverse event, adverse reaction or unexpected adverse reaction that results in death, is life-
threatening, requires hospitalisation or prolongation of existing hospitalization, results in persistent or 
significant disability or incapacity, or consists of a congenital anomaly or birth defect. 
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